Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients

Prevalence and Clinical Evolution of Olfactory and Taste Disorders in Patients Infected by SARS-CoV-2

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04361565

Enrollment

Registered

2020-04-24

Start date

2020-03-20

Completion date

2020-12-31

Last updated

2025-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 by SARS-CoV-2 Infection

Brief summary

A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* COVID-19 diagnosed

Design outcomes

Primary

Measure	Time frame	Description
Duration of the loss of anosmia ageusia	45 days	Duration measured in days
Anosmia	45 days	Prevalence for anosmia in the COVID-19 + patients
Ageusia	45 days	Prevalence for ageusia in the COVID-19 + patients

Countries

France

Outcome results